Core Viewpoint - The article commemorates the life and contributions of J. Michael Bishop, a renowned biologist and Nobel laureate, highlighting his groundbreaking research on cancer origins and his leadership at UCSF [2][10]. Group 1: Early Life and Education - J. Michael Bishop was born on February 22, 1936, in a rural town in Pennsylvania, and completed his early education in a two-room schoolhouse [4]. - He earned a Bachelor’s degree in Chemistry from Gettysburg College in 1957 and obtained his MD from Harvard Medical School in 1962, where he first engaged in scientific research [4]. Group 2: Scientific Discoveries - Bishop, in collaboration with Harold Varmus, challenged the prevailing notion that cancer was solely caused by external viruses, proposing that cancer genes could originate from normal host cell genes [5][8]. - Their pivotal discovery in 1976 demonstrated that the src oncogene in the Rous Sarcoma Virus was derived from normal cellular genes, fundamentally altering the understanding of cancer origins [10]. Group 3: Leadership at UCSF - Bishop served as the eighth president of UCSF from July 1, 1998, to August 2009, marking the longest tenure in the university's history [12]. - He was instrumental in planning and developing the UCSF Mission Bay campus, transforming it into one of the largest academic biomedical expansions in the U.S. [13]. Group 4: Legacy and Honors - In addition to the Nobel Prize, Bishop received numerous accolades, including the Lasker Award and the National Medal of Science, and he served as the director of the National Cancer Advisory Board [15]. - His legacy includes the establishment of the Bishop Cancer Research Institute in Chengdu, China, which focuses on advancing precision cancer research [16].

Core Viewpoint - ADC drugs are gaining global attention as a new generation of precision anti-cancer biopharmaceuticals, with 21 approved and 4 under application for market entry, alongside over 1900 research projects, of which approximately 500 are in clinical stages [1] Industry Overview - The ADC drug market is characterized by active trading, but it faces multiple challenges such as drug resistance and low endocytosis efficiency [1] - Chinese companies have made significant progress in payload iteration and improving internalization efficiency, with firms like Innovent Biologics leading globally [1]

Core Insights - Six out of nine competing companies have been awarded the qualification for the oral formulation of Olaparib, a PARP inhibitor used for treating ovarian and breast cancers, indicating a significant development in the oncology market [1] Company Summary - The companies that received the qualification include: - Huadong Medicine (Xi'an) Bohua Pharmaceutical Co., Ltd. (produced by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. and Shaanxi Jiuzhou Pharmaceutical Co., Ltd.) - Tibet Jinyue Pharmaceutical Co., Ltd. (M/s Natco Pharma Limited) - Shanghai Xuantai Pharmaceutical Technology Co., Ltd. (produced by Jiangsu Xuantai Pharmaceutical Co., Ltd.) - Qilu Pharmaceutical (Hainan) Co., Ltd. - Hunan Kelun Pharmaceutical Co., Ltd. - Shiyao Group Ouyi Pharmaceutical Co., Ltd. [1] Industry Summary - The original manufacturer, AstraZeneca, has lost the bid for the oral formulation of Olaparib, which is the first PARP inhibitor globally and represents a significant advancement in precision oncology [1] - The expected sales revenue for Olaparib in domestic public hospitals is projected to exceed 1 billion yuan in 2024, highlighting its market potential [1]